Abstract Episodic ataxia type 1 (EA1) is an autosomal dominant channelopathy caused by mutations in KCNA1, which encodes the voltage-gated potassium channel, Kv1.1. Eleven members of an EA family were evaluated with molecular and functional studies. A novel c.746T>G (p.Phe249Cys) missense mutation of KCNA1 segregated in the family members with episodic ataxia, myokymia, and malignant hyperthermia susceptibility. No mutations were found in the known malignant h y p e r t h e r m i a g e n e s RY R 1 o r C A C N A 1 S . The Phe249Cys-Kv1.1 channels did not show any currents upon functional expression, confirming a pathogenic role of the mutation. Malignant hyperthermia may be a presentation of KCNA1 mutations, which has significant implications for the clinical care of these patients and illustrates the phenotypic heterogeneity of KCNA1 mutations.
Introduction
Episodic ataxia type 1 (EA1) is an autosomal dominant channelopathy characterized by brief episodes of cerebellar ataxia and dysarthria [1] . Interictal myokymia is typically reported in EA1, but persistent cerebellar features have also been described [2] . EA1 is caused by loss-of-function mutations in the KCNA1 gene encoding the voltage-gated potassium (K + ) channel, Kv1.1 that lead to neuronal hyperexcitability [3] . The onset is typically in early childhood and episodes of ataxia are usually precipitated by physical and emotional stress, startle, or sudden movements [1] . Clinical heterogeneity associated with KCNA1 mutations has been reported, including isolated muscle spasms with rigidity [4] , hearing impairment [5] , cerebellar atrophy, cognitive delay, myokymia and epilepsy [6, 7] , migraine [8] , and distal lower limb weakness and stiffness [9] . Loss of Kv1.1 channel function leads to neuronal hyperexcitability and prolonged duration of action potentials [5] .
Malignant hyperthermia (MH) is a pharmacogenetic disorder
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of the skeletal muscle, secondary to abnormal cellular calcium homeostasis, which has been associated with mutations in the skeletal muscle ryanodine receptor (RYR1) and α1 subunit of the DHPR (CACNA1S) [10] . We report a large family with a history of EA1 and MH that segregated with a novel missense mutation of KCNA1, further expanding the clinical phenotype associated with KCNA1 mutations.
Materials and methods

Subjects
The proband (subject III-15) and ten family members were assessed using a standardized protocol after providing written informed consent. This study was approved by the Research Ethics Board of the Hospital for Sick Children.
Mutation screening
All subjects in generation II were screened for mutations in KCNA1 (MIM# 176260). Additionally, screening of the entire coding regions of RYR1 (MIM# 180901) and CACNA1S (MIM# 114208) was performed in subject II-6 and exome sequencing was performed for the proband (subject III-15) and her father (subject II-6). Direct Sanger and exome sequencing were performed at The Centre for Applied Genomics (TCAG), Toronto, Canada.
Functional studies (available as Supplemental data).
Results
Subjects
Subject III-15
This 18-year-old female had a history of recurrent episodes of gait unsteadiness since age 10, with progression of episode frequency since age 13 ( Fig. 1 , Table 1 ). The episodes lasted between 10 and 60 min and were triggered by sudden unexpected stimuli, but also occurred during sleep. The episodes were preceded by a sensation of warmth spreading over the whole body, followed by a feeling of inebriation and incoordination of the limbs together with slurred speech, blurry vision, and vertigo. Stress was associated with more severe episodes. A post-episode headache was usually present. The exam between episodes was a normal apart from upper limb overshooting during mirror testing and a flickering motion of the fingers. Acetazolamide, carbamazepine, lamotrigine, and topiramate were of no benefit. Routine cardiac (EKG, echocardiogram, and 24-h Holter monitor), metabolic (organic acids, amino acids), and neurological (EMG/NCS, EEG, and MRI) investigations were normal. Genetic testing of CACNA1A, SCN1A, ATP1A2, CACNB4, and SLC1A3 was negative. Exome sequencing did not reveal variants which were bioinformatically predicted to be damaging in any other genes.
The father of subject III-15 had a history compatible with episodic ataxia and tested positive for MH susceptibility using the caffeine/halothane contracture test (CHCT) on skeletal muscle biopsy. His brother (subject II-5) passed away at age 1 year after a surgery due to cardiac arrest in the setting of MH post anesthesia, without administration of dantrolene. Genetic testing of the two genes known to cause the majority of MH susceptibility, RYR1 and CACNA1S, was negative, as was exome sequencing. Additional clinical histories of other family members are available as Supplemental data.
Mutation identification for EA
All family members with symptoms consistent with episodic ataxia carried the c.746T>G (p.Phe249Cys) mutation (Fig. 1) . The mutation also segregated with family members who had a confirmed diagnosis of MH susceptibility (Table 1) . 
Functional analysis
Upon expression of p.Phe249Cys channels in Xenopus oocytes, K + currents could not be detected (Fig. 2) . Wild-type (WT) channels produced robust currents. In simulated heterozygous condition, the K + currents were readily detectable and the voltage dependent-activation was similar to the WT channels (p = 0.082, Fig. 2c ). The tail current amplitude was~1/2 of those in oocytes injected with WT messenger RNA (mRNA) only (same total amount of mRNA) (Fig. 2) . To test if the p.Phe249Cys subunits could form heterotetramers with WT subunits, we made the p.Phe249Cys channel insensitive to TEA block by introducing a Tyr379Val mutation to the same polypeptide as the p.Phe249Cys mutation (Phe249-Tyr379Val) [11] . When co-expressed together with WT subunits in a 1:1 ratio, the sensitivity of WT/Phe249Cys-Tyr379Val channels was reduced (p < 0.001) (Fig. 2d) . However, this reduction in TEA-sensitivity was much smaller than when the WT channels were co-expressed with WT subunits made insensitive to TEA block (Fig. 2d) . To test if the co-expression of p.Phe249Cys may negatively influence the function of the WT subunits, we injected an increasing amount of Phe249Cys mRNA at a constant amount of WT mRNA. As the concentration of p.Phe249Cys mRNA increased, the current amplitude decreased (Fig. 2e) .
Discussion
We report a novel c.746T>G (p.Phe249Cys) mutation of KCNA1 co-segregating in a two-generation family clinically diagnosed with EA or myokymia and MH susceptibility. The Phe249 amino acid residue is located in the intracellular loop between transmembrane segments TM1 and TM2 within the voltage-sensing domain of the Kv1.1 channel. It is highly conserved across species indicating that the phenyalanine at position 249 is essential for normal channel function. The functional studies further support the pathogenicity of the p.Phe249Cys mutation by demonstrating a complete loss-of-function in the homozygous state. In the heterozygous state, the K + current amplitude reduced to half of WT channels and voltage dependence of channel activation was unaltered. These data are consistent with those of the previously characterized mutation affecting the same residue, p.Phe249Ile [11] . In addition, the electrophysiology data suggests that the mutant subunit can co-assemble with the WT subunits and may reduce the functional expression of the heterotetramer in the cell surface. Of interest, in all family members in whom MH susceptibility was documented, the p.Phe249Cys mutation segregated with positive CHCT results. In subject II-6, genetic testing of RYR1 and CACNA1S followed by exome sequencing was negative. These findings raise an important question regarding a potential contribution of the p.Phe249Cys KCNA1 mutation to MH in this family. The fatal MH event in subject II-5 may have been caused by functionally impaired Kv1.1 channels precipitated by exposure to anesthesia. Volatile anesthetics are known to have an inhibitory effect on Kv1.1 channels [12] , and KCNA1 knock-out mice have muscle hyperexcitability [13] . The effect of volatile anesthetics on a mutated channel with reduced current could lead to increase in excitability of the peripheral nervous system, which expresses Kv1.1 channels, and secondarily maintain cardiac and skeletal muscle contraction with dysregulation of Ca 2+ homeostasis. Loss-of-function mutation in Kv1.1 channels may potentially induce a thermoregulatory defect in hypothalamic neurons that mediate rapid core body temperature changes [8] , as seen in MH. We postulate that the p.Phe249Cys KCNA1 mutation could have precipitated the MH event in this family.
In conclusion, we report a novel KCNA1 mutation associated with an EA1 phenotype and a possible association with MH. The current report broadens the phenotypes associated with KCNA1 mutations to include possible susceptibility to MH.
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